||CsnPharm

CAS No.: 714272-27-2

Plinabulin/普那布林 Catalog No. CSN13791

Synonyms: NPI-2358;普那布林

Plinabulin is a vascular disrupting agent (VDA) against tubulin-depolymerizing with IC50 of 9.8~18 nM in tumor cells.

规格	价格	促销价格	库存	数量

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

加入购物车大规格询价

加入收藏

产品咨询

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

纯度 & 质量文件批次:

靶点选择性

生物活性

实验方案

技术信息

生物活性

描述Plinabulin is a vascular disrupting agent (VDA) against tubulin-depolymerizing with IC50 of 9.8~18 nM in tumor cells.
临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT00322608	Cancer	Phase 1	Completed	-	United States, Michigan ... more >> Barbara Ann Karmanos Cancer Institute/Wayne State University Detroit, Michigan, United States, 48201 United States, Texas Institute for Drug Development San Antonio, Texas, United States, 78245-3217 United States, Washington Northwest Medical Specialties Tacoma, Washington, United States, 98405 Collapse <<
NCT03294577	Chemotherapy-induced Neutropen... more >>ia Collapse <<	Phase 2 Phase 3	Recruiting	April 18, 2019	China, Guangzhou ... more >> Cancer Center of Guangzhou Medical University Breast Oncology Recruiting Guangzhou, Guangzhou, China, 510000 Contact: Hongsheng Li, MD China, Harbin Harbin Medical University Cancer Hospital Recruiting Harbin, Harbin, China, 150000 Contact: Qingyuan Zhang, MD China, Shenyang Liaoning Cancer Hospital & Institute Recruiting Shenyang, Shenyang, China, 110000 Contact: Tao Sun, MD Collapse <<
NCT00630110	Cancer	Phase 1 Phase 2	Completed	-	-

更多
参考文献

[1] Bertelsen LB, Shen YY, et al. Vascular effects of plinabulin (NPI-2358) and the influence on tumour response when given alone or combined with radiation. Int J Radiat Biol. 2011 Nov;87(11):1126-34.
[2] Nicholson B, Lloyd GK, et al. NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent. Anticancer Drugs. 2006 Jan;17(1):25-31.

实验方案

计算器摩尔计算器总药量计算器工作液计算器
储存液制备
- 1 mg
- 5 mg
- 10 mg
- 1 mM
- 2.9728 mL
- 14.8638 mL
- 29.7276 mL
- 5 mM
- 0.5946 mL
- 2.9728 mL
- 5.9455 mL
- 10 mM
- 0.2973 mL
- 1.4864 mL
- 2.9728 mL

技术信息

CAS号	714272-27-2	储存条件	粉末液体 -20°C:3-6 月 -80°C:12月
分子式	C19H20N4O2	运输	蓝冰
分子量	336.39	别名	NPI-2358;普那布林

大规格询价

号为必填项

姓名: 邮箱: 手机号:

留言:

提交

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT00322608	Cancer	Phase 1	Completed	-	United States, Michigan ... more >> Barbara Ann Karmanos Cancer Institute/Wayne State University Detroit, Michigan, United States, 48201 United States, Texas Institute for Drug Development San Antonio, Texas, United States, 78245-3217 United States, Washington Northwest Medical Specialties Tacoma, Washington, United States, 98405 Collapse <<
NCT03294577	Chemotherapy-induced Neutropen... more >>ia Collapse <<	Phase 2 Phase 3	Recruiting	April 18, 2019	China, Guangzhou ... more >> Cancer Center of Guangzhou Medical University Breast Oncology Recruiting Guangzhou, Guangzhou, China, 510000 Contact: Hongsheng Li, MD China, Harbin Harbin Medical University Cancer Hospital Recruiting Harbin, Harbin, China, 150000 Contact: Qingyuan Zhang, MD China, Shenyang Liaoning Cancer Hospital & Institute Recruiting Shenyang, Shenyang, China, 110000 Contact: Tao Sun, MD Collapse <<
NCT00630110	Cancer	Phase 1 Phase 2	Completed	-	-
NCT03575793	Lung Cancer S... more >>CLC Collapse <<	Phase 1 Phase 2	Recruiting	September 2022	United States, New Jersey ... more >> Rutgers Cancer Institute of New Jersey Recruiting New Brunswick, New Jersey, United States, 08903 Contact: Jyoti Malhotra 732-235-7521 Jm1940@cinj.rutgers.edu Contact: Michelle Orlick 732-235-6048 orlickmi@cinj.rutgers.edu Principal Investigator: Jyoti Malhotra, MD Collapse <<
NCT02846792	ALK Gene Translocation ... more >> EGFR Activating Mutation Recurrent Non-Small Cell Lung Carcinoma ROS1 Gene Translocation Stage IIIB Non-Small Cell Lung Cancer AJCC v7 Stage IV Non-Small Cell Lung Cancer AJCC v7 Collapse <<	Phase 1 Phase 2	Recruiting	-	United States, Washington ... more >> Fred Hutch/University of Washington Cancer Consortium Recruiting Seattle, Washington, United States, 98109 Contact: Rafael Santana-Davila 206-288-6723 Principal Investigator: Rafael Santana-Davila Collapse <<
NCT02812667	Non-small Cell Lung Cancer Met... more >>astatic Collapse <<	Phase 1	Recruiting	December 2020	United States, California ... more >> UC San Diego Moores Cancer Center Recruiting La Jolla, California, United States, 92093 Contact: Lyudmilla Bazhenova, MD 858-534-1765 lbazhenova@ucsd.edu Collapse <<
NCT03102606	Chemotherapy-induced Neutropen... more >>ia Collapse <<	Phase 2 Phase 3	Recruiting	May 15, 2019	United States, California ... more >> Stanford University School of Medicine - Cancer Institute Not yet recruiting Stanford, California, United States, 94305-5827 Contact: Dougles W Blayney, MD 650-725-6704 dblayney@stanford.edu United States, New York North Shore Hematology/Oncology Associates, P.C. Recruiting East Setauket, New York, United States, 11733 Contact: David Chu, MD 646-319-2862 dchu@nshoa.com Contact: Jeffrey Vacirca, MD 646-319-2862 jvacirca@nshoa.com Collapse <<
NCT02504489	Non-Small Cell Lung Cancer	Phase 3	Recruiting	April 2019	United States, California ... more >> Pacific Cancer Medical Center, Inc. Recruiting Anaheim, California, United States, 92801 Contact: Elizabeth Brown elizabethg@pacificcancer.com Principal Investigator: Veena Charu, MD NICR: Synergy Hematology Oncology Recruiting Los Angeles, California, United States, 90048 Contact: Anton Akulov 323-725-0657 aakulov@nicresearch.com Principal Investigator: Levon Qasabian, MD Innovative Clinical Research Institute Recruiting Whittier, California, United States Contact: Kirsten Bettino kbettino@airesearch.us Principal Investigator: Eddie Thara, MD United States, Colorado Memorial Health Care System Recruiting Colorado Springs, Colorado, United States Contact: Caralyn Hutchens caralyn.henderson@uchealth.org Principal Investigator: Robert Hoyer, MD United States, Georgia Peachtree Hematoloy-Oncology Consultants, PC Recruiting Atlanta, Georgia, United States Contact: Ann Johnston AJohnston@piedmontcancerinstitute.com Principal Investigator: Trevor Feinstein, MD United States, Illinois Carle Cancer Center Recruiting Urbana, Illinois, United States, 61801 Contact: Joshua Ward joshua.ward@carle.com Principal Investigator: Krishna Vasireddy, DO United States, Kentucky University of Louisville-Brown Cancer Center Recruiting Louisville, Kentucky, United States, 40202 Contact: Goetz Kloecker, MD goetz.kloecker@louisville.edu Contact: Karen Carter, RN k.carter@louisville.edu United States, Mississippi Hattiesburg Clinic Hematology/Oncology Recruiting Hattiesburg, Mississippi, United States, 39401 Contact: Tammy McBeth 601-288-2495 tmcbeth@forrestgeneral.com Principal Investigator: John Hrom, MD United States, Ohio University of Cincinnati Not yet recruiting Cincinnati, Ohio, United States, 45267 Contact: Nagia A Karim, MD karimnf@uc.edu Toledo Cancer Center Recruiting Toledo, Ohio, United States, 43623 Contact: Rex B Mowat, MD 419-473-3561 Contact: Jessica Ciesler, RN 419-473-3561 United States, Tennessee Cookeville Regional Medical Center Cancer Center Recruiting Cookeville, Tennessee, United States, 61801 Contact: Linda Moore lamoore@crmchealth.org Principal Investigator: Paul Jacquin, MD Australia, New South Wales Blacktown Cancer Centre Recruiting Blacktown, New South Wales, Australia, 2148 Contact: Adnan Nagrial, MD 61 2 9845 6859 Adnan.Nagrial@health.nsw.gov.au Principal Investigator: Adnan Nagrial, MD Border Medical Oncology Research Unit Recruiting East Albury, New South Wales, Australia, 2640 Contact: Craig Underhill, MD cunderhill@bordermedonc.com.au Principal Investigator: Craig Underhill, MD Gosford Hospital Recruiting Gosford, New South Wales, Australia, 2250 Contact: Matthew Wong, MD Matt.wong@health.nsw.gov.au Principal Investigator: Matthew Wong, MD Australia, Queensland Adult Mater Hospital Recruiting South Brisbane, Queensland, Australia, 4101 Contact: Vikram Jain, MD Vikram.Jain@mater.org.au Principal Investigator: Vikram Jain Australia, Victoria Barwon Health Recruiting Geelong, Victoria, Australia, 3220 Contact: Madhu Singh MSINGH@BarwonHealth.org.au Principal Investigator: Madhu Singh, MD Peninsula and South East Oncology Recruiting Melbourne, Victoria, Australia, 3199 Contact: Vinod Ganju, MD vg@paso.com.au Principal Investigator: Vinod Ganju, MD Epworth Hospital Recruiting Richmond, Victoria, Australia, 3121 Contact: Ross Jennens, MD jennens@bigpond.net.au Principal Investigator: Ross Jennens, MD Australia, Western Australia Fiona Stanley Hospital Recruiting Murdoch, Western Australia, Australia, 6150 Contact: Andrew Kiberu, MD Andrew.Kiberu@health.wa.gov.au Principal Investigator: Andrew Kiberu, MD Perth Oncology/Mount Hospital Recruiting Perth, Western Australia, Australia, 6000 Contact: Guy van Hazel, MD guy@perthoncology.com.au Principal Investigator: Guy van Hazel, MD St John of God Hospital, Subiaco Recruiting Subiaco, Western Australia, Australia, 6008 Contact: Tim Clay, MD drclayoncologist@gmail.com Principal Investigator: Tim Clay, MD Collapse <<

Plinabulin/普那布林 Catalog No. CSN13791

靶点选择性

请登录您的专属账户

确认信息